The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.10
Bid: 12.90
Ask: 13.30
Change: -0.10 (-0.76%)
Spread: 0.40 (3.101%)
Open: 13.20
High: 13.20
Low: 13.05
Prev. Close: 13.20
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Great Western notes good assays; Guild signs Villalba

Mon, 06th Dec 2021 19:18

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Great Western Mining Corp PLC - gold, silver and copper explorer and developer in US state of Nevada - Says 12 holes at OMCO intersect elevated gold grades with the tailings thicker than expected. Says a total of 67 individual assays were examined with average grades of 1.25 grams per tonne, in a range of 0.17 to 3.76 grams per tonne. "The independent assay results of this large volume of pre-mined material are far ahead of our expectations and an important milestone in establishing the basis for a commercial processing operation on a much larger scale than envisaged at Mineral Jackpot alone. We are carefully reviewing processing options, including contained cyanide leaching, and looking at the potential economies of creating a combined facility for the processing of OMCO tailings and the spoil material from the Mineral Jackpot claims. We will keep shareholders informed at every stage," Chair Brian Hall says.

----------

GCP Student Living PLC - London-focused student accommodation investor - Says Competition & Markets Authority has decided not to refer GCP's takeover by Gemini Jersey JV LP to a phase 2 investigation. GCP agreed to a GBP969 million takeover back in July from a consortium which includes student accommodation provider Scape Living and also iQSA Holdco. Scape is funded by funds managed by APG, an investor in GCP, and iQSA by funds advised by Blackstone. At the beginning of November, company said it expects acquisition to complete before 2021 end. iQSA Holdco Ltd noted the decision.

----------

Guild Esports PLC - London-based esports company - Signs Nicolas Villalba, or Nicolas99fc, as the newest member of its football game FIFA roster. "Nicolas, from Argentina, has ranked in the top 3 FIFA players worldwide since 2018 and is Argentina's second highest earner within esports, with USD290,000 in lifetime earnings to date. His most notable international major wins include the FIFA 19 PS4 Playoffs and the FIFA 19 eClub World Cup," company notes.

----------

Yew Grove REIT PLC - invests in Irish office and industrial properties outside Dublin's central business district - Quanta Capital Asset Management Ltd, in conjunction with investment manager Davy, confirms that Goldstein Property ICAV, a 4.2% shareholder in Yew Grove, does not intend to make an offer for Yew Grove. On Friday, Quanta confirmed it will not make an offer for Yew Grove, after expressing interest in late November. Earlier in November, Yew Grove accepted a EUR127.8 million cash takeover offer from Slate Office Ireland Investment Ltd, an indirect subsidiary of Slate Office REIT. Slate offered EUR1.017 per share, plus the 1.20 cents dividend declared by Yew Grove for the third quarter.

----------

Foresight Sustainable Forestry Co PLC - forestry investment trust, managed by private equity firm Foresight Group LLP - Notes completion of two acquisitions of substantial new afforestation opportunities in Scotland. Blackmead Forestry II Ltd, which the company has an option to acquire, has fully completed the purchase of two "substantial and ideally located" afforestation opportunities in Dumfries and Galloway. "The acquisition of these sites cements two more substantial afforestation opportunities within our target seed portfolio that will both drive attractive risk-adjusted returns for investors, whilst also directly contributing to the fight against the twin threats of climate change and biodiversity loss," company says.

----------

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces strategic partnership with molecular science and technology company Texas-based Caris Life Sciences to hasten phase 2 study recruitment in the US. "The partnership will leverage Caris' comprehensive whole transcriptome sequencing and whole exome sequencing platform assay, real-world data and its right-in-time clinical trial solutions to enhance the speed of US accruals for Redx's Phase 2 trial for the investigational Porcupine inhibitor, RXC004, in genetically-selected patients with Wnt-ligand dependent microsatellite stable metastatic colorectal cancer," company says.

----------

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Inks option agreement with University College Dublin for a melioidosis vaccine candidate, MelioVac, and a licence to evaluate five other infectious disease portfolio assets. "The company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust award to aid its development, as well as five of other potential vaccine candidates discovered by Associate Professor McClean and her team, for the duration of the option agreement, prior to signing a licence agreement," company says. Associate Professor Siobhan McClean is the inventor of MelioVac. Says it has identified melioidosis as an infectious disease of interest due to its rising incidence around the world and because there is currently no approved vaccine available. "Concerns are growing about global warming contributing to the spread of the disease to traditionally non-tropical areas," it says.

----------

Journeo PLC - Ashby-de-la-Zouch, England-based information systems and transport technical services firm - Nets a public transport information systems contract for the supply of its displays technology and software in North Wales. Contract is worth GBP800,000. "The breadth of display technologies, stretching from ultra-low power ePaper displays suitable for rural locations where authorities cannot deliver power to the display location, to full-colour LED displays suitable for high-traffic transport corridors, will be managed using the company's content management software," company says.

----------

Distribution Finance Capital Holdings PLC - Manchester-based bank providing personal savings products - Expects full year financial performance to be in line with the board's expectations. Expects its loan book to close the year in the range of GBP250 million to GBP275 million. Loan book is at GBP243 million at November 30, up from GBP202 million at end-September, and more than doubling since the start of the year. Expects to announce its full year end trading update during the middle of January 2022.

----------

Beowulf Mining PLC - developing Kallak iron ore project and the Aitolampi natural flake graphite project - Says Finnish subsidiary Grafintec Oy signs joint venture with Epsilon Advanced Materials Private Ltd, a subsidiary of India-based manufacturer of coal tar derivatives Epsilon Carbon Private Ltd. JV is for the establishment of an anode materials production facility to be located in Finland. The JV will supply battery and cell manufacturing companies in Europe, complementing Epsilon Advanced Materials' growing anode materials business in India. Grafintec will own 49% of the JV.

----------

Okyo Pharma Ltd - London-based biotechnology firm focused on dry eye diseases and chronic pain - Expects to file IND in the third quarter of next year for OK-101 in the treatment of dry eye disease. OK-101 is the company's lead pre-clinical compound and a novel long-acting, G protein-coupled receptor-based anti-inflammatory drug candidate. OK-101 is anticipated to start human studies with a Phase 2 clinical trial in DED patients in the fourth quarter of 2022. The trial is anticipated to be conducted in approximately 100 to 200 DED patients. "Based on the anti-inflammatory response seen in pre-clinical models, this novel mechanism of action may prove to be a breakthrough treatment for the over 700 million DED patients globally," company says.

----------

SolGold PLC - Brisbane, Australia-based developer of copper-gold deposits in Ecuador - Says drill holes 14 to 22 at Cacharposa intersect mineralisation in Ecuador at the Porvenir held by subsidiary Green Rock Resources SA. Says work is advancing on a maiden mineral resource estimate for the Cacharposa deposit that is expected later this month. Drilling is ongoing with three drill rigs on site testing mineralisation. "Results from Cacharposa continue to improve with Hole 19 representing one of the best intersections to date at the Porvenir project. Mineralisation in this hole commenced from surface and attests to the economic potential of this project. Cacharposa continues to grow and with numerous other nearby mineralised targets identified, we believe the Porvenir project has the potential to become a Tier 1 copper - gold porphyry camp," says Head of Exploration Jason Ward.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.